The Estée Lauder Companies has signed a joint development agreement with biotech firm Atropos Therapeutics Inc., San Carlos, CA. The focus is of the accord is to explore the botanical space for molecules that modulate senescence, according to the company. “Atropos' in-depth understanding of and its unique and well validated approaches to identify senescence modulators will synergize well with our expertise in the natural product space.  Botanically derived senosuppressors are no...